Loading
Bleximenib is an experimental small-molecule drug from Janssen Research & Development in phase 3 trials for acute myeloid leukaemia, with its target not yet stated publicly.
Bleximenib (JNJ-75276617) is a small-molecule drug developed by Janssen Research & Development. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06852222 (A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukaemia (AML)), in acute myeloid leukaemia. The largest, NCT06852222, plans to enrol 600 participants with primary completion expected 2029-06-22. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.
1.Bleximenib slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Bleximenib" OR ABSTRACT:"Bleximenib" OR TITLE:"JNJ-75276617" OR ABSTRACT:"JNJ-75276617") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bleximenib, not a curated reading list.
Shares NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia and the tag pipeline.
Shares NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.
Shares Johnson & Johnson and the tag pipeline.